Kadmon Holdings, Inc.
http://kadmon.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Kadmon Holdings, Inc.
Keeping Track: Kadmon Chooses RTOR For Belumosudil; NDAs For Novel Imaging Agents And Liquid Anticonvulsants
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Kadmon’s ROCKstar Is Rising On GvHD Therapy Data
Kadmon’s treatment for graft-versus-host disease, belumosudil continues to perform well in its pivotal ROCKstar study, setting the stage for a US filing under the FDA’s pilot Real-Time Oncology Review program.
Deal Watch: Pfizer Licenses Skin-Targeted JAK Inhibitor Portfolio From Theravance
Deal with Pfizer makes for Theravance’s third large pharma partnership since 2016. AbbVie off-loads Marinol to India’s Alkem, Bausch licenses candidate for rare form of dry eye disease from Novaliq.
Keeping Track: Pfizer’s Talzenna Ensures Record Year For Novel US Approvals; Novartis Submits SMA Gene Therapy
The latest drug development news and highlights from our FDA Performance Tracker.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
- Large Molecule
- Other Names / Subsidiaries
-
- Kadmon Corporation, LLC
- Phytoceutical
- Romeck Pharma, LLC
- Three Rivers Pharmaceuticals, LLC